OTCPK:LCDX

Stock Analysis Report

Caliber Imaging & Diagnostics

Executive Summary

Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Caliber Imaging & Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.7%

LCDX

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-58.5%

LCDX

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: LCDX underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: LCDX underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

LCDXIndustryMarket
7 Day7.7%2.0%1.8%
30 Day-1.8%-1.8%-0.7%
90 Day-21.1%-0.5%0.06%
1 Year-58.5%-58.5%14.2%13.3%9.7%7.3%
3 Year-6.7%-6.7%70.5%65.3%46.3%36.9%
5 Year8.7%8.7%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Caliber Imaging & Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Caliber Imaging & Diagnostics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Caliber Imaging & Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Caliber Imaging & Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LCDX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Caliber Imaging & Diagnostics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Caliber Imaging & Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Caliber Imaging & Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LCDX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Caliber Imaging & Diagnostics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Caliber Imaging & Diagnostics performed over the past 5 years?

17.0%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Caliber Imaging & Diagnostics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Caliber Imaging & Diagnostics's financial position?


In this section we usually analyse Caliber Imaging & Diagnostics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Caliber Imaging & Diagnostics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of LCDX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Caliber Imaging & Diagnostics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Caliber Imaging & Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LCDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LCDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LCDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LCDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LCDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Caliber Imaging & Diagnostics's salary, the management and board of directors tenure and is there insider trading?

7.8yrs

Average management tenure


CEO

L. Hone (69yo)

7.8yrs

Tenure

US$752,434

Compensation

Mr. L. Michael Hone has been the Chief Executive Officer of Caliber Imaging & Diagnostics, Inc. (alternate name: Lucid, Inc.) since December 7, 2011. He served as an Executive officer at Lattice Incorporat ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether L.'s total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare L.'s compensation with company performance.


Management Age and Tenure

7.8yrs

Average Tenure

69yo

Average Age

Experienced Management: LCDX's management team is seasoned and experienced (7.8 years average tenure).


Board Age and Tenure

7.5yrs

Average Tenure

68.5yo

Average Age

Experienced Board: LCDX's board of directors are considered experienced (7.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • L. Hone (69yo)

    CEO & Director

    • Tenure: 7.8yrs
    • Compensation: US$752.43k
  • Bill Shea (71yo)

    Executive Chairman

    • Tenure: 8.8yrs
    • Compensation: US$223.57k
  • William Fox (53yo)

    CTO & VP of Technology Operations

    • Tenure: 14.8yrs
    • Compensation: US$183.87k
  • Bob Kelley

    Vice President of Sales and Marketing

    • Tenure: 0yrs
  • Karen Howe

    Chief Financial Officer

    • Tenure: 1.3yrs

Board Members

  • L. Hone (69yo)

    CEO & Director

    • Tenure: 7.8yrs
    • Compensation: US$752.43k
  • Bill Shea (71yo)

    Executive Chairman

    • Tenure: 8.8yrs
    • Compensation: US$223.57k
  • Rocco Maggiotto (68yo)

    Independent Director

    • Tenure: 8.7yrs
    • Compensation: US$67.07k
  • Paul Stuka (64yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$44.72k
  • Bill O'Dell (72yo)

    Director

    • Tenure: 5.4yrs
  • Daniel Siegel (61yo)

    Director

    • Tenure: 5.8yrs

Company Information

Caliber Imaging & Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Caliber Imaging & Diagnostics, Inc.
  • Ticker: LCDX
  • Exchange: OTCPK
  • Founded: 1991
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.803m
  • Shares outstanding: 8.58m
  • Website: https://www.caliberid.com

Number of Employees


Location

  • Caliber Imaging & Diagnostics, Inc.
  • 100 Burtt Road
  • Suite 203
  • Andover
  • Massachusetts
  • 1810
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LCDXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2012

Biography

Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides Viva ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:04
End of Day Share Price2019/10/17 00:00
Earnings2014/03/31
Annual Earnings2013/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.